CDT Equity Inc., a data-driven biopharmaceutical company, focuses on identifying, enhancing, and monetising therapeutic assets. The company's pipeline includes AZD1656, a glucokinase activator that is in Phase II trials for the treatment of autoimmune disorders, including uveitis, Hashimoto's thyroiditis, preterm labor, and renal transplant; AZD5658, which is in Phase I clinical trial for the treatment of Type 2 Diabetes Mellitus; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. It also provides treatments for inflammatory disorders, oncology, dermatology, rare diseases and animal health. The company was formerly known as Conduit Pharmaceuticals Inc. and changed its name to CDT Equity Inc. in August 2025. The company was founded in 2019 and is based in Naples, Florida.
Frequently asked questions
What sector does Conduit Pharmaceuticals Inc. (CDT) operate in?
Conduit Pharmaceuticals Inc. belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Conduit Pharmaceuticals Inc. (CDT) current stock price?
As of the latest data, Conduit Pharmaceuticals Inc. stock price is $3.23, with a previous close of $3.59. Conduit Pharmaceuticals Inc. lost -$0.36 in the last trading session, representing a -10.03% loss.
What is Conduit Pharmaceuticals Inc. (CDT) current market capitalization?
Conduit Pharmaceuticals Inc. market cap is approximately 15.69 million.
What is Conduit Pharmaceuticals Inc. (CDT) Earnings Per Share (EPS)?
The trailing EPS is -$1,197.13.
What is Conduit Pharmaceuticals Inc. (CDT) EBITDA?
Conduit Pharmaceuticals Inc. EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is 108.69 million.
Does Conduit Pharmaceuticals Inc. (CDT) pay dividends?
No. Conduit Pharmaceuticals Inc. does not pay a dividend.
When is Conduit Pharmaceuticals Inc. (CDT) next earnings report?
Conduit Pharmaceuticals Inc. is expected to release its next earnings report on June 30, 2026.
What is Conduit Pharmaceuticals Inc. (CDT) beta (volatility) score?
Conduit Pharmaceuticals Inc. has a beta of 1.457, suggesting it is more volatile than the market.
